drugset / Trial / NCT06206915
Phase I Study of XZ120 in Malignant Tumors
Phase 1
Not yet recruiting
123 enrolled
Shandong New Time Pharmaceutical Co., LTD
Fudan University · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast cancer. Research purpose: to evaluate XZ120 safety, tolerability, for the treatment of malignant tumor patients pharmacokinetic characteristics and preliminary effectiveness.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-02-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XZ120 | Unknown | 0.75 mg/m2 | Intravenous |
| Subject | XZ120 | Unknown | 1.5 mg/m2 | Intravenous |
| Subject | XZ120 | Unknown | 2.25 mg/m2 | Intravenous |
| Subject | XZ120 | Unknown | 3 mg/m2 | Intravenous |